The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.

• To determine the maximum tolerated dose (MTD) of EPO906 administered in combination with radiation therapy and establish a recommend phase II dose.
• To evaluate the safety and toxicity profile of EPO906 when administered concurrently with radiotherapy in three disease cohorts.
• To evaluate tumor response.

Inclusion Criteria:

• Requires a minimum of 3 weeks of radiation therapy
• Solid tumors with advanced or recurrent disease for which there is no standard therapy or tumors have failed standard therapy
• World Health Organization (WHO) performance status equal to or less than 2
• Life expectancy equal to or greater than 3 months

Exclusion Criteria:

• Any peripheral neuropathy
• Unresolved diarrhea greater than grade 1
• Patients who received any other investigational compound within the past 28 days
• Severe cardiac insufficiency
• Patients on Coumadin